ANXA2 and glioblastoma: As a result, control cells disseminated covering a 60-fold larger area than ANXA2 antibody treated cells (Figure 5B), demonstrating that ANXA2 inhibition is able to completely block GBM cell invasiveness also in an in vivo setting.